{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:39:46Z","timestamp":1792658386797,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.diabres.2026.113586","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:22:23Z","timestamp":1791008543000},"page":"113586","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Hospitalization outcomes in adults with type 2 diabetes mellitus treated with once-weekly insulin efsitora versus once-daily basal insulins: A post hoc analysis of the QWINT-1 to \u22124 randomized trials"],"prefix":"10.1016","volume":"242","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3986-9630","authenticated-orcid":false,"given":"Athena","family":"Philis-Tsimikas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9295-3225","authenticated-orcid":false,"given":"Rodolfo J.","family":"Galindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6211-464X","authenticated-orcid":false,"given":"Bruno","family":"Guerci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca J.","family":"Threlkeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bellina","family":"Mushala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C P","family":"Shyam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Goldyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2026.113586_b0005","unstructured":"International Diabetes Federation. IDF Diabetes Atlas. 11th ed. Global factsheet. Brussels; 2025."},{"key":"10.1016\/j.diabres.2026.113586_b0010","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S2213-8587(15)00362-9","article-title":"Lifetime risk of developing impaired glucose metabolism and eventual progression from prediabetes to type 2 diabetes: a prospective cohort study","volume":"4","author":"Ligthart","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2026.113586_b0015","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2337\/dci18-0007","article-title":"Economic costs of diabetes in the U.S. in 2017","volume":"41","author":"American Diabetes Association","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2026.113586_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.109862","article-title":"Proportions and trends of adult hospitalizations with diabetes, United States, 2000-2018","volume":"187","author":"Zhang","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2026.113586_b0025","doi-asserted-by":"crossref","first-page":"106","DOI":"10.2337\/dc19-0653","article-title":"Trends in rates of infections requiring hospitalization among adults with versus without diabetes in the U.S., 2000-2015","volume":"43","author":"Harding","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2026.113586_b0030","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.19099","article-title":"Association of cumulative multimorbidity, glycemic control, and medication use with hypoglycemia-related emergency department visits and hospitalizations among adults with diabetes","volume":"3","author":"McCoy","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.diabres.2026.113586_b0035","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2502796","article-title":"Weekly fixed-dose insulin efsitora in type 2 diabetes without previous insulin therapy","volume":"393","author":"Rosenstock","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113586_b0040","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1111\/dom.15259","article-title":"Efficacy and safety of once\u2010weekly versus once\u2010daily basal insulin analogues in the treatment of type 2 diabetes mellitus: a systematic review and meta\u2010analysis","volume":"25","author":"Karakasis","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2026.113586_b0045","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11892-026-01628-3","article-title":"Efficacy and safety of once-weekly basal insulin analogs versus daily basal insulin analogs in adults with type 2 diabetes: a systematic review and meta-analysis","volume":"26","author":"Raptis","year":"2026","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.diabres.2026.113586_b0050","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1007\/s13300-025-01745-4","article-title":"Insights on hospitalisations from the phase 3a ONWARDS 1-6 trials of once-weekly insulin icodec","volume":"16","author":"Philis-Tsimikas","year":"2025","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.diabres.2026.113586_b0055","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/14656566.2026.2667324","article-title":"Evaluating once-weekly insulin efsitora alfa for adults with type 2 diabetes","volume":"27","author":"Ramachandran","year":"2026","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.diabres.2026.113586_b0060","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1111\/dom.15604","article-title":"Once-weekly insulin efsitora alfa: design and rationale for the QWINT phase 3 clinical development programme","volume":"26","author":"Bergenstal","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2026.113586_b0065","unstructured":"European Medicines Agency. CHMP summary of positive opinion for Onswik. 2026. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/onswik#overview2026."},{"key":"10.1016\/j.diabres.2026.113586_b0070","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/dom.14956","article-title":"Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes","volume":"25","author":"Heise","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2026.113586_b0075","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1016\/S0140-6736(25)01044-X","article-title":"Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial","volume":"405","author":"Philis-Tsimikas","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2026.113586_b0080","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1056\/NEJMoa2403953","article-title":"Insulin efsitora versus degludec in type 2 diabetes without previous insulin treatment","volume":"391","author":"Wysham","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113586_b0085","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1016\/S0140-6736(25)01069-4","article-title":"Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial","volume":"405","author":"Blevins","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2026.113586_b0090","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2213-8587(21)00288-6","article-title":"Trends in leading causes of hospitalisation of adults with diabetes in England from 2003 to 2018: an epidemiological analysis of linked primary care records","volume":"10","author":"Pearson-Stuttard","year":"2022","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726005061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726005061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:59:25Z","timestamp":1792655965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726005061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":18,"alternative-id":["S0168822726005061"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113586","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hospitalization outcomes in adults with type 2 diabetes mellitus treated with once-weekly insulin efsitora versus once-daily basal insulins: A post hoc analysis of the QWINT-1 to \u22124 randomized trials","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113586","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113586"}}